Opinion
Video
Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers
The panel emphasizes the role of multidisciplinary tumor boards in optimizing oncology care in nonmelanoma skin cancers.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Patel provided an overview of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), the 2 most common types of nonmelanoma skin cancer. He explained that cSCC and BCC arise from keratinocytes in the epidermis and can present as rough, scaly patches or nodules that continue to grow and won’t heal. Pisano highlighted that cSCC and especially BCC are extremely common, with incidence rising as the population ages. She noted that cSCC is responsible for more cancer deaths annually than melanoma or Merkel cell carcinoma. Hamid then discussed immunotherapy with PD-1 inhibitors as a new standard of care for advanced cSCC and BCC. Hamid concluded that immunotherapy not only drives responses in advanced keratinocyte carcinomas but exhibits durability that could form the backbone of future combination regimens.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
